Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey - YUMUK, PERRAN FULDEN (ELSEVIER SCIENCE INC, 2019)
Keywords: ALK positive; ROS1 positive; Lorlatinib; Advanced stage lung cancer